Monitor for future S-1/S-3 filing to register shares from conversion, which could lead to immediate selling pressure. The 25% premium on principal ($350k paid for $437.5k face value) and discount conversion terms suggest distressed financing, potentially signaling cash flow concerns.
Price Chart
Executive Summary
CERO Therapeutics raised $350,000 through a convertible note with a $437,500 principal, creating a direct financial obligation and unregistered securities issuance. The note carries a 10% interest rate, matures in April 2027, and is convertible into common stock at a discount, indicating distressed financing terms.
Key Financial Metrics
Key Facts
- CERO issued a convertible promissory note for $350,000 purchase price with $437,500 principal value to Keystone Capital Partners, LLC
- Note bears 10% annual interest, matures April 9, 2027, and is convertible into common stock
- Conversion price is the lesser of $0.05 or 80% of the average of the 5 lowest intraday trading prices over the 20 days prior to conversion
- Company committed to file an S-1 or S-3 registration for resale of shares issuable upon conversion
- Note issuance was exempt under Section 4(a)(2) and Rule 506(b) of the Securities Act
Financial Impact
Immediate dilution risk from convertible note with $437,500 principal and 10% interest, convertible at significant discount to market
Risk Factors
- Significant shareholder dilution upon conversion at discounted price
- High interest burden at 10% annual rate
- Potential for additional dilutive financing if company draws on remaining $562,500 available under the note
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-043519 |
| Document: 0001213900-26-043519-index-headers.html | 0001213900-26-043519 |
| Document: 0001213900-26-043519-index.html | 0001213900-26-043519 |
| Document: 0001213900-26-043519.txt | 0001213900-26-043519 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers